Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.
Pillai R, LeBoeuf SE, Hao Y, New C, Blum JLE, Rashidfarrokhi A, Huang SM, Bahamon C, Wu WL, Karadal-Ferrena B, Herrera A, Ivanova E, Cross M, Bossowski JP, Ding H, Hayashi M, Rajalingam S, Karakousi T, Sayin VI, Khanna KM, Wong KK, Wild R, Tsirigos A, Poirier JT, Rudin CM, Davidson SM, Koralov SB, Papagiannakopoulos T. Pillai R, et al. Among authors: poirier jt. Sci Adv. 2024 Mar 29;10(13):eadm9859. doi: 10.1126/sciadv.adm9859. Epub 2024 Mar 27. Sci Adv. 2024. PMID: 38536921 Free PMC article.
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, Sánchez-Rivera FJ, Subbaraj L, Martinez B, Bronson RT, Prigge JR, Schmidt EE, Thomas CJ, Goparaju C, Davies A, Dolgalev I, Heguy A, Allaj V, Poirier JT, Moreira AL, Rudin CM, Pass HI, Vander Heiden MG, Jacks T, Papagiannakopoulos T. Romero R, et al. Among authors: poirier jt. Nat Med. 2017 Nov;23(11):1362-1368. doi: 10.1038/nm.4407. Epub 2017 Oct 2. Nat Med. 2017. PMID: 28967920 Free PMC article.
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.
Zavitsanou AM, Pillai R, Hao Y, Wu WL, Bartnicki E, Karakousi T, Rajalingam S, Herrera A, Karatza A, Rashidfarrokhi A, Solis S, Ciampricotti M, Yeaton AH, Ivanova E, Wohlhieter CA, Buus TB, Hayashi M, Karadal-Ferrena B, Pass HI, Poirier JT, Rudin CM, Wong KK, Moreira AL, Khanna KM, Tsirigos A, Papagiannakopoulos T, Koralov SB. Zavitsanou AM, et al. Among authors: poirier jt. Cell Rep. 2023 Nov 28;42(11):113295. doi: 10.1016/j.celrep.2023.113295. Epub 2023 Oct 26. Cell Rep. 2023. PMID: 37889752 Free PMC article.
MYC, MAX, and small cell lung cancer.
Rudin CM, Poirier JT. Rudin CM, et al. Among authors: poirier jt. Cancer Discov. 2014 Mar;4(3):273-4. doi: 10.1158/2159-8290.CD-14-0069. Cancer Discov. 2014. PMID: 24596200
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.
Pillai R, LeBoeuf SE, Hao Y, New C, Blum JLE, Rashidfarrokhi A, Huang SM, Bahamon C, Wu WL, Karadal-Ferrena B, Herrera A, Ivanova E, Cross M, Bossowski JP, Ding H, Hayashi M, Rajalingam S, Karakousi T, Sayin VI, Khanna KM, Wong KK, Wild R, Tsirigos A, Poirier JT, Rudin CM, Davidson SM, Koralov SB, Papagiannakopoulos T. Pillai R, et al. Among authors: poirier jt. bioRxiv [Preprint]. 2023 Jun 28:2023.06.27.546750. doi: 10.1101/2023.06.27.546750. bioRxiv. 2023. PMID: 37425844 Free PMC article. Updated. Preprint.
Histone Code Aberrancies in Small Cell Lung Cancer.
Gardner EE, Poirier JT, Rudin CM. Gardner EE, et al. Among authors: poirier jt. J Thorac Oncol. 2017 Apr;12(4):599-601. doi: 10.1016/j.jtho.2017.02.008. J Thorac Oncol. 2017. PMID: 28343540 Free article. No abstract available.
Unravelling the biology of SCLC: implications for therapy.
Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Sabari JK, et al. Among authors: poirier jt. Nat Rev Clin Oncol. 2017 Sep;14(9):549-561. doi: 10.1038/nrclinonc.2017.71. Epub 2017 May 23. Nat Rev Clin Oncol. 2017. PMID: 28534531 Free PMC article. Review.
Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma.
Dolgalev I, Zhou H, Murrell N, Le H, Sakellaropoulos T, Coudray N, Zhu K, Vasudevaraja V, Yeaton A, Goparaju C, Li Y, Sulaiman I, Tsay JJ, Meyn P, Mohamed H, Sydney I, Shiomi T, Ramaswami S, Narula N, Kulicke R, Davis FP, Stransky N, Smolen GA, Cheng WY, Cai J, Punekar S, Velcheti V, Sterman DH, Poirier JT, Neel B, Wong KK, Chiriboga L, Heguy A, Papagiannakopoulos T, Nadorp B, Snuderl M, Segal LN, Moreira AL, Pass HI, Tsirigos A. Dolgalev I, et al. Among authors: poirier jt. Nat Commun. 2023 Nov 8;14(1):6764. doi: 10.1038/s41467-023-42327-x. Nat Commun. 2023. PMID: 37938580 Free PMC article.
98 results